MRI contrast developer Epix Medical is planning a follow-on public offering of its common stock. The 4.3 million shares would be offered from a registration statement covering shares that became effective in January, according to the Cambridge, MA-based firm. SG Cowen and Wells Fargo Securities are co-lead managers of the offering, and the underwriters will receive an option to purchase an additional 645,000 shares within 30 days to cover over-allotments, Epix said.
By AuntMinnie.com staff writersJuly 28, 2003
Related Reading
Epix shows slight revenue increase, lower loss in Q2, July 25, 2003
Epix completes final phase III trials on MRA contrast agent, July 11, 2003
Epix, Schering to partner on MRI contrast, May 27, 2003
Epix revenues gain, losses widen, April 25, 2003
Epix to develop new MR agent, April 1, 2003
Copyright © 2003 AuntMinnie.com
